ADVA Biotechnology
Automated Platform for Autologous Cell Manufacturing
Company Overview
Snapshot
Founded in September 2016 by Tal Slonim, Ron Elazary-Vulcani, Barbara Paldus, and Ohad Karnieli, ADVA Biotechnology operates with 11–50 employees. The company has secured funding across 3 rounds from 2 investors. In September 2024, ADVA Biotechnology received a grant from the Israel Innovation Authority.
Business overview
ADVA Biotechnology develops enabling technologies for cell therapy manufacturing, focusing on solutions for autologous cell therapy. The company's core product, ADVA X3, is a robust, modular cGMP system designed for automated, single-use, end-to-end cell manufacturing. This platform aims to optimize, ensure quality, and reduce costs and time-to-market for autologous cell therapies, serving the healthcare and life sciences industries, particularly in pharmaceuticals and providers.
Strategic signal
In August 2022, ADVA Biotechnology and Lonza expanded their collaboration, agreeing to broaden the availability and use of automated bioreactors through a license to Lonza's patents. This partnership signals a strategic move to enhance the reach and application of ADVA Biotechnology's automated manufacturing solutions within the cell therapy market, indicating strong validation of their technology and potential for increased market penetration.
Log in to access full profile ›Company Intelligence Q&A
- What is ADVA Biotechnology's primary offering?
- ADVA Biotechnology develops the ADVA X3, an automated platform for autologous cell manufacturing, designed as a cGMP system with a single-use, end-to-end solution for cell therapy production.
- When was ADVA Biotechnology founded and by whom?
- ADVA Biotechnology was founded in September 2016 by Tal Slonim, Ron Elazary-Vulcani, Barbara Paldus, and Ohad Karnieli.
- What significant partnership did ADVA Biotechnology announce in August 2022?
- In August 2022, ADVA Biotechnology and Lonza agreed to expand the availability and use of automated bioreactors, including a license to Lonza's patents, to enhance cell therapy manufacturing capabilities.
- What is the strategic impact of the ADVA X3 device on cancer treatments?
- In January 2021, news highlighted that the ADVA X3 device can automate the production of CAR-T cells, making personalized cancer treatments more accessible and cost-effective by enabling hospitals to produce customized drugs for patients.
- What grant did ADVA Biotechnology receive in September 2024?
- In September 2024, ADVA Biotechnology received a grant from the Israel Innovation Authority.